Table of Contents
ISRN Pulmonology
Volume 2012 (2012), Article ID 452307, 10 pages
http://dx.doi.org/10.5402/2012/452307
Review Article

Controversies Surrounding the Potential Use of Histone Deacetylase Inhibitors for the Treatment of Asthma

1Allergy and Immune Disorders, Murdoch Children’s Research Institute, Parkville, VIC, Australia
2Department of Pathology, The University of Melbourne, Parkville, VIC, Australia
3Epigenomic Medicine, Baker IDI Heart and Diabetes Institute, The Alfred Medical Research and Education Precinct, Melbourne, VIC, Australia

Received 18 October 2011; Accepted 5 December 2011

Academic Editors: A. Altraja, K. Ito, and C. C. Witt

Copyright © 2012 Simon G. Royce et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. R. Myers and L. Tomasio, “Asthma: 2015 and beyond,” Respiratory Care, vol. 56, no. 9, pp. 1389–1410, 2011. View at Publisher · View at Google Scholar
  2. N. R. Bhakta and P. G. Woodruff, “Human asthma phenotypes: from the clinic, to cytokines, and back again,” Immunological Reviews, vol. 242, no. 1, pp. 220–232, 2011. View at Publisher · View at Google Scholar
  3. J. A. Elias, C. G. Lee, T. Zheng, B. Ma, R. J. Homer, and Z. Zhu, “New insights into the pathogenesis of asthma,” The Journal of Clinical Investigation, vol. 111, no. 3, pp. 291–297, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. C. M. Evans, K. Kim, M. J. Tuvim, and B. F. Dickey, “Mucus hypersecretion in asthma: causes and effects,” Current Opinion in Pulmonary Medicine, vol. 15, no. 1, pp. 4–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Djukanovic, W. R. Roche, J. W. Wilson et al., “Mucosal inflammation in asthma,” American Review of Respiratory Disease, vol. 142, no. 2, pp. 434–457, 1990. View at Google Scholar · View at Scopus
  6. D. R. Curran and L. Cohn, “Advances in mucous cell metaplasia: a plug for mucus as a therapeutic focus in chronic airway disease,” American Journal of Respiratory Cell and Molecular Biology, vol. 42, no. 3, pp. 268–275, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. S. T. Holgate, “Pathogenesis of asthma,” Clinical and Experimental Allergy, vol. 38, no. 6, pp. 872–897, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. L. R. Bisset and P. Schmid-Grendelmeier, “Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective,” Current Opinion in Pulmonary Medicine, vol. 11, no. 1, pp. 35–42, 2005. View at Google Scholar · View at Scopus
  9. P. J. Barnes, “The role of inflammation and anti-inflammatory medication in asthma,” Respiratory Medicine, vol. 96, no. 1, supplement A, pp. S9–S15, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. P. J. Barnes, “Immunology of asthma and chronic obstructive pulmonary disease,” Nature Reviews Immunology, vol. 8, no. 3, pp. 183–192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. P. J. Barnes, “Pathophysiology of allergic inflammation,” Immunological Reviews, vol. 242, no. 1, pp. 31–50, 2011. View at Publisher · View at Google Scholar
  12. I. M. Adcock, P. C. Chou, A. Durham, and P. Ford, “Overcoming steroid unresponsiveness in airways disease,” Biochemical Society Transactions, vol. 37, no. 4, pp. 824–829, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. P. J. Barnes and I. M. Adcock, “Glucocorticoid resistance in inflammatory diseases,” The Lancet, vol. 373, no. 9678, pp. 1905–1917, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. K. F. Chung, G. Caramori, and I. M. Adcock, “Inhaled corticosteroids as combination therapy with β-adrenergic agonists in airways disease: present and future,” European Journal of Clinical Pharmacology, vol. 65, no. 9, pp. 853–871, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. I. M. Adcock and P. J. Barnes, “Molecular mechanisms of corticosteroid resistance,” Chest, vol. 134, no. 2, pp. 394–401, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. P. J. Barnes, “Mechanisms and resistance in glucocorticoid control of inflammation,” Journal of Steroid Biochemistry and Molecular Biology, vol. 120, no. 2-3, pp. 76–85, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. I. M. Adcock, P. A. Ford, P. Bhavsar, T. Ahmad, and K. F. Chung, “Steroid resistance in asthma: mechanisms and treatment options,” Current Allergy and Asthma Reports, vol. 8, no. 2, pp. 171–178, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. P. J. Barnes, “Glucocorticosteroids: current and future directions,” British Journal of Pharmacology, vol. 163, no. 1, pp. 29–43, 2011. View at Publisher · View at Google Scholar
  19. K. Mullane, “The increasing challenge of discovering asthma drugs,” Biochemical Pharmacology, vol. 82, no. 6, pp. 586–599, 2011. View at Publisher · View at Google Scholar
  20. R. A. Nathan, “Anti-leukotriene agents: a new direction in asthma therapy,” Journal of Asthma, vol. 33, no. 6, pp. 353–366, 1996. View at Google Scholar · View at Scopus
  21. P. J. Barnes, “Anti-leukotrienes: a new treatment for asthma,” Practitioner, vol. 242, no. 1586, pp. 395–399, 1998. View at Google Scholar · View at Scopus
  22. A. R. Leff, “Regulation of leukotrienes in the management of asthma: biology and clinical therapy,” Annual Review of Medicine, vol. 52, pp. 1–14, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. “FDA approves zafirlukast, first of new type of asthma drug,” American Journal of Health-System Pharmacy, vol. 53, article 2778, 1996.
  24. “Montelukast approved for asthma management,” American Journal of Health-System Pharmacy, vol. 55, article 759, 1998.
  25. A. M. Stevenson, “Leukotriene receptor antagonists: the newest in asthma drugs,” The American Journal of Maternal Child Nursing, vol. 22, no. 3, pp. 170–169, 1997. View at Google Scholar · View at Scopus
  26. F. Tarantini, I. Baiardini, G. Passalacqua, F. Braido, and G. W. Canonica, “Asthma treatment: ‘Magic bullets which seek their own targets’,” Allergy, vol. 62, no. 6, pp. 605–610, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. C. Catley, J. Coote, M. Bari, and K. L. Tomlinson, “Monoclonal antibodies for treatment of asthma,” Pharmacology & Therapeutics, vol. 132, no. 3, pp. 333–351, 2011. View at Google Scholar
  28. “Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25,” BioDrugs, vol. 16, pp. 380–386, 2002.
  29. R. E. Jonkers and J. S. van der Zee, “Anti-IgE and other new immunomodulation-based therapies for allergic asthma,” Netherlands Journal of Medicine, vol. 63, no. 4, pp. 121–128, 2005. View at Google Scholar · View at Scopus
  30. A. H. Liu, “Treatment of asthma with anti-immunoglobulin E monoclonal antibody,” Allergy and Asthma Proceedings, vol. 27, no. 2, pp. S24–S28, 2006. View at Google Scholar · View at Scopus
  31. T. Kouzarides, “Chromatin modifications and their function,” Cell, vol. 128, no. 4, pp. 693–705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. P. A. Marks, “Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions,” Biochimica et Biophysica Acta, vol. 1799, no. 10–12, pp. 717–725, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. P. A. Marks and W. S. Xu, “Histone deacetylase inhibitors: potential in cancer therapy,” Journal of Cellular Biochemistry, vol. 107, no. 4, pp. 600–608, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Minucci and P. G. Pelicci, “Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer,” Nature Reviews Cancer, vol. 6, no. 1, pp. 38–51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Y. Roth, J. M. Denu, and C. D. Allis, “Histone acetyltransferases,” Annual Review of Biochemistry, vol. 70, pp. 81–120, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. B. C. Smith and J. M. Denu, “Chemical mechanisms of histone lysine and arginine modifications,” Biochimica et Biophysica Acta, vol. 1789, no. 1, pp. 45–57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Dokmanovic, C. Clarke, and P. A. Marks, “Histone deacetylase inhibitors: overview and perspectives,” Molecular Cancer Research, vol. 5, no. 10, pp. 981–989, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Dokmanovic and P. A. Marks, “Prospects: histone deacetylase inhibitors,” Journal of Cellular Biochemistry, vol. 96, no. 2, pp. 293–304, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. T. A. McKinsey, E. N. Olson, and Berger, “Dual roles of histone deacetylases in the control of cardiac growth,” Novartis Foundation Symposium, vol. 259, pp. 132–141, 2004. View at Google Scholar · View at Scopus
  40. A. J. M. de Ruijter, A. H. van Gennip, H. N. Caron, S. Kemp, and A. B. P. van Kuilenburg, “Histone deacetylases (HDACs): characterization of the classical HDAC family,” Biochemical Journal, vol. 370, no. 3, pp. 737–749, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. I. V. Gregoretti, Y. M. Lee, and H. V. Goodson, “Molecular evolution of the histone deacetylase family: Ffunctional implications of phylogenetic analysis,” Journal of Molecular Biology, vol. 338, no. 1, pp. 17–31, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Landry, A. Sutton, S. T. Tafrov et al., “The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 11, pp. 5807–5811, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. M. C. Haigis and L. P. Guarente, “Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction,” Genes and Development, vol. 20, no. 21, pp. 2913–2921, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Landry, J. T. Slama, and R. Sternglanz, “Role of NAD+ in the deacetylase activity of the SIR2-like proteins,” Biochemical and Biophysical Research Communications, vol. 278, no. 3, pp. 685–690, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. K. G. Tanner, J. Landry, R. Sternglanz, and J. M. Denu, “Silent information regulator 2 family of NAD-dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 26, pp. 14178–14182, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. B. C. Smith, W. C. Hallows, and J. M. Denu, “Mechanisms and molecular probes of sirtuins,” Chemistry and Biology, vol. 15, no. 10, pp. 1002–1013, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. R. A. Frye, “Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins,” Biochemical and Biophysical Research Communications, vol. 273, no. 2, pp. 793–798, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Guarente and C. Kenyon, “Genetic pathways that regulate ageing in model organisms,” Nature, vol. 408, no. 6809, pp. 255–262, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Gems, “Yeast longevity gene goes public,” Nature, vol. 410, no. 6825, pp. 154–155, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. A. L. Barlow, C. M. van Drunen, C. A. Johnson, S. Tweedie, A. Bird, and B. M. Turner, “dSIR2 and dHDAC6: Ttwo novel, inhibitor-resistant deacetylases in Drosophila melanogaster,” Experimental Cell Research, vol. 265, no. 1, pp. 90–103, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. J. G. Wood, B. Rogina, S. Lavu et al., “Sirtuin activators mimic caloric restriction and delay ageing in metazoans,” Nature, vol. 430, pp. 686–689, 2004. View at Google Scholar
  52. L. Guarente and F. Picard, “Calorie restriction—the SIR2 connection,” Cell, vol. 120, no. 4, pp. 473–482, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Bordone and L. Guarente, “Calorie restriction, SIRT1 and metabolism: understanding longevity,” Nature Reviews Molecular Cell Biology, vol. 6, no. 4, pp. 298–305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Michan and D. Sinclair, “Sirtuins in mammals: insights into their biological function,” Biochemical Journal, vol. 404, no. 1, pp. 1–13, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. P. J. Elliott and M. Jirousek, “Sirtuins: novel targets for metabolic disease,” Current Opinion in Investigational Drugs, vol. 9, no. 4, pp. 371–378, 2008. View at Google Scholar · View at Scopus
  56. M. E. Giannakou and L. Partridge, “The interaction between FOXO and SIRT1: tipping the balance towards survival,” Trends in Cell Biology, vol. 14, no. 8, pp. 408–412, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. N. Chaudhary and P. T. Pfluger, “Metabolic benefits from Sirt1 and Sirt1 activators,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 12, no. 4, pp. 431–437, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. M. C. Sugden, P. W. Caton, and M. J. Holness, “PPAR control: it's SIRTainly as easy as PGC,” Journal of Endocrinology, vol. 204, no. 2, pp. 93–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Camins, F. X. Sureda, F. Junyent et al., “Sirtuin activators: designing molecules to extend life span,” Biochimica et Biophysica Acta, vol. 1799, no. 10–12, pp. 740–749, 2010. View at Publisher · View at Google Scholar
  60. S. Chung, H. Yao, S. Caito, J. W. Hwang, G. Arunachalam, and I. Rahman, “Regulation of SIRT1 in cellular functions: role of polyphenols,” Archives of Biochemistry and Biophysics, vol. 501, no. 1, pp. 79–90, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Fröjdö, C. Durand, and L. Pirola, “Metabolic effects of resveratrol in mammals—a link between improved insulin action and aging,” Current Aging Science, vol. 1, no. 3, pp. 145–151, 2008. View at Google Scholar · View at Scopus
  62. S. Sadruddin and R. Arora, “Resveratrol: biologic and therapeutic implications,” Journal of the CardioMetabolic Syndrome, vol. 4, no. 2, pp. 102–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. M. D. Knutson and C. Leeuwenburgh, “Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases,” Nutrition Reviews, vol. 66, no. 10, pp. 591–596, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. L. G. Wood, P. A. B. Wark, and M. L. Garg, “Antioxidant and anti-inflammatory effects of resveratrol in airway disease,” Antioxidants and Redox Signaling, vol. 13, no. 10, pp. 1535–1548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Pervaiz and A. L. Holme, “Resveratrol: its biologic targets and functional activity,” Antioxidants and Redox Signaling, vol. 11, no. 11, pp. 2851–2897, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Yang, T. Zhang, and Y. Ito, “Large-scale separation of resveratrol, anthraglycoside A and anthraglycoside B from Polygonum cuspidatum Sieb. et Zucc by high-speed counter-current chromatography,” Journal of Chromatography A, vol. 919, no. 2, pp. 443–448, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Yadav, S. Jain, A. Bhardwaj et al., “Biological and medicinal properties of grapes and their bioactive constituents: an update,” Journal of Medicinal Food, vol. 12, no. 3, pp. 473–484, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. W. R. Leifert and M. Y. Abeywardena, “Cardioprotective actions of grape polyphenols,” Nutrition Research, vol. 28, no. 11, pp. 729–737, 2008. View at Publisher · View at Google Scholar
  69. G. J. Soleas, E. P. Diamandis, and D. M. Goldberg, “Resveratrol: a molecule whose time has come? And gone?” Clinical Biochemistry, vol. 30, no. 2, pp. 91–113, 1997. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Signorelli and R. Ghidoni, “Resveratrol as an anticancer nutrient: molecular basis, open questions and promises,” Journal of Nutritional Biochemistry, vol. 16, no. 8, pp. 449–466, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. N. R. Sundaresan, V. B. Pillai, and M. P. Gupta, “Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy,” Journal of Molecular and Cellular Cardiology, vol. 51, no. 4, pp. 614–618, 2011. View at Publisher · View at Google Scholar
  72. T. Hsieh and J. M. Wu, “Resveratrol: biological and pharmaceutical properties as anticancer molecule,” BioFactors, vol. 36, no. 5, pp. 360–369, 2010. View at Publisher · View at Google Scholar
  73. C. C. Udenigwe, V. R. Ramprasath, R. E. Aluko, and P. J. H. Jones, “Potential of resveratrol in anticancer and anti-inflammatory therapy,” Nutrition Reviews, vol. 66, no. 8, pp. 445–454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. B. L. Liu, X. Zhang, W. Zhang, and H. N. Zhen, “New enlightenment of French paradox: resveratrol's potential for cancer chemoprevention and anti-cancer therapy,” Cancer Biology and Therapy, vol. 6, no. 12, pp. 1833–1836, 2007. View at Google Scholar · View at Scopus
  75. L. E. Donnelly, R. Newton, G. E. Kennedy et al., “Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms,” American Journal of Physiology, vol. 287, no. 4, pp. L774–L783, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Lee, S. Kim, O. K. Kwon, S. R. Oh, H. K. Lee, and K. Ahn, “Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma,” International Immunopharmacology, vol. 9, no. 4, pp. 418–424, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. S. G. Royce, W. Dang, Y. Gao et al., “Resveratrol has protective effects against airway remodeling and airway inflammation in a murine model of allergic airways disease,” Pathobiology of Aging & Age-Related Diseases, vol. 1, article 7134, 2011. View at Google Scholar
  78. S. R. Kim, K. S. Lee, S. J. Park et al., “Involvement of sirtuin 1 in airway inflammation and hyperresponsiveness of allergic airway disease,” Journal of Allergy and Clinical Immunology, vol. 125, no. 2, pp. 449–460, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. J. E. Bolden, M. J. Peart, and R. W. Johnstone, “Anticancer activities of histone deacetylase inhibitors,” Nature Reviews Drug Discovery, vol. 5, no. 9, pp. 769–784, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. P. A. Marks, R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller, and W. K. Kelly, “Histone deacetylases and cancer: causes and therapies,” Nature Reviews Cancer, vol. 1, no. 3, pp. 194–202, 2001. View at Google Scholar · View at Scopus
  81. R. W. Johnstone, “Histone-deacetylase inhibitors: novel drugs for the treatment of cancer,” Nature Reviews Drug Discovery, vol. 1, no. 4, pp. 287–299, 2002. View at Google Scholar · View at Scopus
  82. G. Estiu, N. West, R. Mazitschek, E. Greenberg, J. E. Bradner, and O. Wiest, “On the inhibition of histone deacetylase 8,” Bioorganic and Medicinal Chemistry, vol. 18, no. 11, pp. 4103–4110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. J. Ahringer, “NuRD and SIN3: histone deacetylase complexes in development,” Trends in Genetics, vol. 16, no. 8, pp. 351–356, 2000. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. Huang, S. J. Myers, and R. Dingledine, “Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes,” Nature Neuroscience, vol. 2, no. 10, pp. 867–872, 1999. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. D. Wen, V. Perissi, L. M. Staszewski et al., “The histone deacetylase-3 complex contains nuclear receptor corepressors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 13, pp. 7202–7207, 2000. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Martin, R. Kettmann, and F. Dequiedt, “Class IIa histone deacetylases: regulating the regulators,” Oncogene, vol. 26, no. 37, pp. 5450–5467, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. O. Witt, H. E. Deubzer, T. Milde, and I. Oehme, “HDAC family: what are the cancer relevant targets?” Cancer Letters, vol. 277, no. 1, pp. 8–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Mai, D. Rotili, S. Valente, and A. G. Kazantsev, “Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise,” Current Pharmaceutical Design, vol. 15, no. 34, pp. 3940–3957, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. W. S. Xu, R. B. Parmigiani, and P. A. Marks, “Histone deacetylase inhibitors: molecular mechanisms of action,” Oncogene, vol. 26, no. 37, pp. 5541–5552, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. J. J. Kovacs, P. J. M. Murphy, S. Gaillard et al., “HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor,” Molecular Cell, vol. 18, no. 5, pp. 601–607, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Haberland, R. L. Montgomery, and E. N. Olson, “The many roles of histone deacetylases in development and physiology: implications for disease and therapy,” Nature Reviews Genetics, vol. 10, no. 1, pp. 32–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. I. M. Adcock, L. Tsaprouni, P. Bhavsar, and K. Ito, “Epigenetic regulation of airway inflammation,” Current Opinion in Immunology, vol. 19, no. 6, pp. 694–700, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. P. J. Barnes, “Histone deacetylase-2 and airway disease,” Therapeutic Advances in Respiratory Disease, vol. 3, no. 5, pp. 235–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. P. Bhavsar, T. Ahmad, and I. M. Adcock, “The role of histone deacetylases in asthma and allergic diseases,” Journal of Allergy and Clinical Immunology, vol. 121, no. 3, pp. 580–584, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. P. J. Barnes, I. M. Adcock, and K. Ito, “Histone acetylation and deacetylation: importance in inflammatory lung diseases,” European Respiratory Journal, vol. 25, no. 3, pp. 552–563, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. K. Ito, C. E. Charron, and I. M. Adcock, “Impact of protein acetylation in inflammatory lung diseases,” Pharmacology and Therapeutics, vol. 116, no. 2, pp. 249–265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. I. M. Adcock, K. Ito, and P. J. Barnes, “Histone deacetylation: an important mechanism in inflammatory lung diseases,” COPD, vol. 2, no. 4, pp. 445–455, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Waltregny, W. Glénisson, S. L. Tran et al., “Histone deacetylase HDAC8 associates with smooth muscle α-actin and is essential for smooth muscle cell contractility,” The FASEB Journal, vol. 19, no. 8, pp. 966–968, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. Y. Zhang, N. Li, C. Caron et al., “HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo,” The EMBO Journal, vol. 22, no. 5, pp. 1168–1179, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. F. A. A. Kwa, A. Balcerczyk, P. Licciardi, A. El-Osta, and T. C. Karagiannis, “Chromatin modifying agents—the cutting edge of anticancer therapy,” Drug Discovery Today, vol. 16, no. 13-14, pp. 543–547, 2011. View at Publisher · View at Google Scholar
  101. M. J. Peart, G. K. Smyth, R. K. van Laar et al., “Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 10, pp. 3697–3702, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. C. Campàs-Moya, “Romidepsin for the treatment of cutaneous t-cell lymphoma,” Drugs of Today, vol. 45, no. 11, pp. 787–795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. P. A. Marks and R. Breslow, “Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug,” Nature Biotechnology, vol. 25, no. 1, pp. 84–90, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Duvic and J. Vu, “Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma,” Expert Opinion on Investigational Drugs, vol. 16, no. 7, pp. 1111–1120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. C. Grant, F. Rahman, R. Piekarz et al., “Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors,” Expert Review of Anticancer Therapy, vol. 10, no. 7, pp. 997–1008, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Yoshida, M. Kijima, M. Akita, and T. Beppu, “Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A,” The Journal of Biological Chemistry, vol. 265, no. 28, pp. 17174–17179, 1990. View at Google Scholar · View at Scopus
  107. P. A. Marks, “The clinical development of histone deacetylase inhibitors as targeted anticancer drugs,” Expert Opinion on Investigational Drugs, vol. 19, no. 9, pp. 1049–1066, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. R. A. Blaheta and J. Cinatl, “Anti-tumor mechanisms of valproate: a novel role for an old drug,” Medicinal Research Reviews, vol. 22, no. 5, pp. 492–511, 2002. View at Publisher · View at Google Scholar · View at Scopus
  109. C. U. Johannessen, “Mechanisms of action of valproate: a commentatory,” Neurochemistry International, vol. 37, no. 2-3, pp. 103–110, 2000. View at Publisher · View at Google Scholar · View at Scopus
  110. G. Rosenberg, “The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?” Cellular and Molecular Life Sciences, vol. 64, no. 16, pp. 2090–2103, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. B. G. Cosío, B. Mann, K. Ito et al., “Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 2, pp. 141–147, 2004. View at Google Scholar
  112. K. Ito, G. Caramori, S. Lim et al., “Expression and activity of histone deacetylases in human asthmatic airways,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 3, pp. 392–396, 2002. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Hew, P. Bhavsar, A. Torrego et al., “Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 2, pp. 134–141, 2006. View at Publisher · View at Google Scholar · View at Scopus
  114. P. J. Barnes, “How corticosteroids control inflammation: quintiles Prize Lecture 2005,” British Journal of Pharmacology, vol. 148, no. 3, pp. 245–254, 2006. View at Publisher · View at Google Scholar · View at Scopus
  115. K. Ito, S. J. Getting, and C. E. Charron, “Mode of glucocorticoid actions in airway disease,” The Scientific World Journal, vol. 6, pp. 1750–1769, 2006. View at Publisher · View at Google Scholar · View at Scopus
  116. K. Ito, S. Lim, G. Caramori et al., “A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 13, pp. 8921–8926, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. P. J. Barnes and R. A. Pauwels, “Theophylline in the management of asthma: time for reappraisal?” European Respiratory Journal, vol. 7, no. 3, pp. 579–591, 1994. View at Google Scholar · View at Scopus
  118. Z. H. Jaffar, P. Sullivan, C. Page, and J. Costello, “Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics,” European Respiratory Journal, vol. 9, no. 3, pp. 456–462, 1996. View at Publisher · View at Google Scholar · View at Scopus
  119. S. Lim, K. Tomita, G. Carramori et al., “Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 2, pp. 273–276, 2001. View at Google Scholar
  120. P. Sullivan, S. Bekir, Z. Jaffar, C. Page, P. Jeffery, and J. Costello, “Anti-inflammatory effects of low-dose oral theophylline in atopic asthma,” The Lancet, vol. 343, no. 8904, pp. 1006–1008, 1994. View at Publisher · View at Google Scholar · View at Scopus
  121. A. J. M. Ward, M. McKenniff, J. M. Evans, C. P. Page, and J. F. Costello, “Theophylline—an immunomodulatory role in asthma?” American Review of Respiratory Disease, vol. 147, no. 3, pp. 518–523, 1993. View at Google Scholar · View at Scopus
  122. D. J. Evans, D. A. Taylor, O. Zetterstrom, K. F. Chung, B. J. O'Connor, and P. J. Barnes, “A comparison of low-dose inhaled budesonide plus theophylline and high- dose inhaled budesonide for moderate asthma,” The New England Journal of Medicine, vol. 337, no. 20, pp. 1412–1418, 1997. View at Publisher · View at Google Scholar · View at Scopus
  123. A. Markham and D. Faulds, “Theophylline. A review of its potential steroid sparing effects in asthma,” Drugs, vol. 56, no. 6, pp. 1081–1091, 1998. View at Publisher · View at Google Scholar · View at Scopus
  124. D. Ukena, U. Harnest, R. Sakalauskas et al., “Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma,” European Respiratory Journal, vol. 10, no. 12, pp. 2754–2760, 1997. View at Publisher · View at Google Scholar · View at Scopus
  125. Y. To, K. Ito, Y. Kizawa et al., “Targeting phosphoinositide-3-kinase-δ with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 7, pp. 897–904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. N. Mercado, Y. To, K. Ito, and P. J. Barnes, “Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-δ,” Journal of Pharmacology and Experimental Therapeutics, vol. 337, no. 2, pp. 465–470, 2011. View at Publisher · View at Google Scholar
  127. J. H. Choi, S. W. Oh, M. S. Kang, H. J. Kwon, G. T. Oh, and D. Y. Kim, “Trichostatin A attenuates airway inflammation in mouse asthma model,” Clinical and Experimental Allergy, vol. 35, no. 1, pp. 89–96, 2005. View at Publisher · View at Google Scholar · View at Scopus
  128. E. S. K. Assem, K. H. Peh, B. Y. C. Wan, B. J. Middleton, J. Dines, and C. M. Marson, “Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction,” International Immunopharmacology, vol. 8, no. 13-14, pp. 1793–1801, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. H. Dombrowsky, M. Barrenschee, M. Kunze, and S. Uhlig, “Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch,” Pulmonary Pharmacology and Therapeutics, vol. 22, no. 6, pp. 593–602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  130. A. Banerjee, C. M. Trivedi, G. Damera et al., “Trichostatin a abrogates airway constriction, but not inflammation in 2 mouse and human asthma models,” American Journal of Respiratory Cell and Molecular Biology, vol. 46, no. 2, pp. 132–138, 2012. View at Google Scholar
  131. M. Lomia, Z. Chapichadze, M. Pruidze, and P. Platonov, “Efficacy of monotherapy with carbamazepine and valproic acid in patients with bronchial asthma: is asthma a neurological disease?” The Internet Journal of Neurology, vol. 4, no. 1, 2005. View at Google Scholar
  132. B. Sayar and O. Polvan, “Epilepsy and bronchial asthma,” The Lancet, vol. 1, no. 7550, p. 1038, 1968. View at Google Scholar · View at Scopus
  133. H. Stevens, “Allergy and epilepsy,” Epilepsia, vol. 6, no. 3, pp. 205–216, 1965. View at Google Scholar · View at Scopus
  134. S. G. Royce, W. Dang, K. Ververis et al., “Protective effects of valproic acid against airway hyperresponsiveness and airway remodeling in a mouse model of allergic airways disease,” Epigenetics, vol. 6, no. 12, pp. 1463–1470, 2011. View at Publisher · View at Google Scholar